Repurposing vaccine-induced anti-HBV antibodies for endogenous immunotherapy against EGFR-positive tumors
A nanobody chimera composed of an EGFR-targeting nanobody and the LOOP1 peptide derived from HBV surface antigen is capable of harnessing HBV vaccine-induced immunity for cancer immunotherapy.
Authors
- Zijiang Zhang (ORCID: https://orcid.org/0000-0001-7167-9821)
- Zhimeng Wu (ORCID: https://orcid.org/0000-0001-7583-7268)
- Haofei Hong (ORCID: https://orcid.org/0000-0003-2139-9666)
- Yanchun Li (ORCID: https://orcid.org/0000-0003-3781-4166)
Institutions
- Jiangnan University (CN)
Publication Details
- Journal
- Chemical Communications
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1039/d5cc03243a
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00